Skip to main content

Table 3 Lung function (COPD-6™, spirometry) according to the presence and severity of COPD according to GOLD stages

From: Diagnostic accuracy of a pocket screening spirometer in diagnosing chronic obstructive pulmonary disease in general practice: a cross sectional validation study using tertiary care as a reference

  Lung function All Non-COPD COPD
GOLD 1
COPD
GOLD 2
Statistics
(N = 227) (n = 184) (n = 24) (n = 19)
COPD-6™ FEV1 (% predicted) 94.3 ± 15.6 97.6 ± 13.3 90.9 ± 13.0 67.5 ± 12.2 F = 46.27 P < 0.001
FEV6 (% predicted) 93.9 ± 16.2 96.0 ± 15.3 94.7 ± 14.9 74.5 ± 13.7 F = 17.27 P < 0.001
FEV1/FEV6 (%) 0.845 ± 0.085 0.864 ± 0.071 0.781 ± 0.083 0.757 ± 0.117 F = 25.84 P < 0.001
Lung age (yrs) 60.7 ± 13.9 57.7 ± 11.1 64.0 ± 11.1 84.6 ± 15.7 F = 48.07 P < 0.001
Spirometry FEV1 (% predicted) 97.9 ± 15.3 101.5 ± 12.9 92.9 ± 10.2 71.1 ± 12.7 F = 51.50 P < 0.001
FVC (% predicted) 109.3 ± 17.0 110.8 ± 16.7 112.7 ± 11.8 91.1 ± 16.2 F = 13.29 P < 0.001
FEV1/FVC (%) 0.742 ± 0.073 0.761 ± 0.060 0.665 ± 0.055 0.650 ± 0.073 F = 49.14 P < 0.001
ΔFEV1 (%) 1.39 ± 4.00 1.40 ± 3.79 2.92 ± 4.25 −0.93 ± 7.68 F = 3.011 P = 0.051
  1. Data for all variables is presented as mean ± standard deviation; FEV 1 forced expiratory volume in 1 s, FEV 6 forced expiratory volume in 6 s, FVC forced expiratory volume, ΔFEV 1 post-bronchodilator change in FEV1 (measured 20 min after inhalation of 400 μg of salbutamol), F – result of ANOVA for between group comparisons